Labiotech.eu

News and Trends 22 Dec 2022

Positive Dupixent eosinophilic esophagitis phase 3 results

The New England Journal of Medicine has published results from a positive phase 3 trial showing adults and adolescents treated with Dupixent (dupilumab) 300 mg weekly experienced significant improvements in signs and symptoms of eosinophilic esophagitis (EoE), which were sustained for up to one year. EoE is a chronic, progressive inflammatory disease that damages the […]

December 22, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 22 Dec 2022

Japanese companies look to reduce environmental impact

Japanese companies Astellas Pharma Inc., Eisai Co., Ltd., Daiichi Sankyo Company, Limited, and Takeda Pharmaceutical Company Limited have agreed a collaboration to reduce the environmental impact of pharmaceutical packaging. Based on the agreement, the four companies will aim to promote the use of more environmentally-friendly packaging for pharmaceutical products by sharing knowledge on packaging technologies […]

December 22, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 22 Dec 2022

Spanish foodtech grows in 2022

Eatable Adventures, an agrifood accelerator, has presented the data from its annual study “The State of Foodtech in Spain 2022.” The report gathers information on the characterization and investment evolution of the Spanish foodtech entrepreneurial ecosystem. The report says 2022 has been a positive year for the sector in the country. Despite the macroeconomic context, […]

December 22, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 21 Dec 2022

Watch: Biocant Park – a biotech hub in the heart of Portugal

Biocant Park is a science and technology park specializing in biotechnology, with a unique innovation environment among the sector in Portugal. Located in Cantanhede, between Porto and Lisbon, the park aims to promote, develop and apply advanced knowledge in life sciences. Currently, the park has four buildings with laboratories and offices for companies, and a […]

December 21, 2022 - 1 minutemin - By Jim Cornall

More News! 21 Dec 2022

Watch: Aphaia Pharma interview

Aphaia Pharma is a Zug, Switzerland, headquartered clinical-stage biopharmaceutical company. It harnesses proprietary precision-targeted drug delivery technology to restore endogenous hormone release in the gastrointestinal tract to treat and prevent metabolic disorders such as obesity and associated diseases. Aphaia Pharma’s lead candidate, APH-012, a glucose formulation, has been shown to safely restore endogenous hormone release […]

December 21, 2022 - 1 minutemin - By Jim Cornall

News and Trends 21 Dec 2022

Watch: Araris Biotech at Bio-Europe

Araris Biotech AG is a Swiss-headquartered company pioneering the development of its novel antibody-drug-conjugate (ADC)-linker technology to enable efficient and precise production of ADCs. Its linker platform enables the attachment of any drug payload to ‘off the shelf’ antibodies, without the need for prior antibody engineering. The resulting ADCs have shown very high activity at […]

December 21, 2022 - 2 minutesmins - By Jim Cornall

Mauritius EDB Economic Development Board

News and Trends 21 Dec 2022

Watch: Mauritius – clinical trials and emerging biotech hub

The Economic Development Board (EDB) in Mauritius commenced its operations as a statutory body in 2018 following the merger between the Board of Investment, Enterprise Mauritius and the Financial Services Promotion Agency. The overarching objective of the EDB is to ensure greater coherence and effectiveness in implementing policies and draw the vision for the economic […]

December 21, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 21 Dec 2022

Biomica raises $20M to advance microbiome-based therapeutics pipeline

Biomica Ltd., a subsidiary of Evogene Ltd., has signed a definitive agreement for a $20 million financing round, to be led by Shanghai Healthcare Capital (SHC). The financing is subject to customary closing conditions, including clearance by Chinese regulatory authorities. The financing round will enable Biomica to develop its pipeline of microbiome-based therapeutics. The company […]

December 21, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 21 Dec 2022

Poolbeg identifies new potential drug candidates for RSV infections

Poolbeg Pharma says it has successfully identified potential new drug candidates from its respiratory syncytial virus (RSV) artificial intelligence (AI) program with OneThree Biotech, Inc. Since initiating the collaboration in February 2022, Poolbeg’s scientific team has worked with OneThree to build a tailored AI approach that leverages Poolbeg’s RSV human challenge trial data to identify […]

December 21, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 21 Dec 2022

Ethris and DIOSynVax to develop mRNA betacoronavirus vaccine

Ethris GmbH is to collaborate with U.K.-based DIOSynVax to jointly develop a protective mRNA vaccine candidate against a broad range of betacoronaviruses. The efforts will utilize Ethris’ mRNA modification and design technologies as well as its lipidoid nanoparticle (LNP) and stabilization platforms. The collaboration is founded on a $42 million award to DIOSynVax by the […]

December 21, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 21 Dec 2022

Anocca secures €25M to develop next-generation T-cell therapies for cancer

Anocca, a fully integrated cell therapy biotechnology company, has secured €25 million ($26.5 million) venture debt financing from the European Investment Bank (EIB). Anocca’s CEO and co-founder Reagan Jarvis said: “We’re delighted that the EIB has chosen to support us as we build a critical piece of advanced biotechnology capability and infrastructure in Sweden. Anocca’s […]

December 21, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 21 Dec 2022

Stem cell plasters could revolutionize heart surgeries

Researchers at the University of Bristol in the U.K. funded by the British Heart Foundation (BHF) have developed ‘stem cell plasters’ to revolutionize the way surgeons treat children living with congenital heart disease, so they don’t need as many open-heart operations. Heart defects are the most common type of anomaly that develop before a baby […]

December 21, 2022 - 4 minutesmins - By Jim Cornall

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Positive Dupixent eosinophilic esophagitis phase 3 results

Japanese companies look to reduce environmental impact

Spanish foodtech grows in 2022

Watch: Biocant Park – a biotech hub in the heart of Portugal

Watch: Aphaia Pharma interview

Watch: Araris Biotech at Bio-Europe

Watch: Mauritius – clinical trials and emerging biotech hub

Biomica raises $20M to advance microbiome-based therapeutics pipeline

Poolbeg identifies new potential drug candidates for RSV infections

Ethris and DIOSynVax to develop mRNA betacoronavirus vaccine

Anocca secures €25M to develop next-generation T-cell therapies for cancer

Stem cell plasters could revolutionize heart surgeries

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!